Skip to Main Content

Paper Details

A Multiparameter Molecular Classifier to Predict Response to Neoadjuvant Lapatinib plus Trastuzumab without Chemotherapy in HER2+ Breast Cancer.
Clin Cancer Res
4
2023
Breast Cancer, ER, HER2, HER2 protein, HER2+, HER2+ breast cancer, HER2-, HER2-E, Lapatinib, PAMELA, PIK3CA, PIK3CA wild-type, PIK3CA-WT, TBCRC023, Trastuzumab, breast cancer, estrogen, estrogen receptor, estrogen receptor-positive (ER+) tumors, lapatinib, pCR, patients, trastuzumab, tumors
Author NameAffiliation
Tomás PascualHospital Clinic de Barcelona
Tomás Pascual
Pier SelenicaMemorial Sloan Kettering Cancer Center
Anna C PavlickBaylor College of Medicine
Anna C PavlickDan L. Duncan Comprehensive Cancer Center, Baylor College of Medicine
Rita NandaUniversity of Chicago
Anna Maria StornioloIndiana University School of Medicine
Ian E KropDana Farber Cancer Institute
Matthew P GoetzMayo Clinic
Julie NangiaDan L. Duncan Comprehensive Cancer Center, Baylor College of Medicine
Antonio C WolffJohns Hopkins University
Britta WeigeltMemorial Sloan Kettering Cancer Center
Jorge S Reis-FilhoMemorial Sloan Kettering Cancer Center
Susan G HilsenbeckBaylor College of Medicine
Susan G HilsenbeckDan L. Duncan Comprehensive Cancer Center, Baylor College of Medicine
Susan G HilsenbeckBaylor College of Medicine
Charles Kent OsborneBaylor College of Medicine
Charles Kent OsborneDan L. Duncan Comprehensive Cancer Center, Baylor College of Medicine
Charles Kent OsborneBaylor College of Medicine
Charles Kent OsborneBaylor College of Medicine
Mothaffar F RimawiBaylor College of Medicine
Mothaffar F RimawiDan L. Duncan Comprehensive Cancer Center, Baylor College of Medicine
Mothaffar F RimawiBaylor College of Medicine
  • 1 - 23

Datasets

Release 1.2